Celina Borges Migliavaca

Celina Borges Migliavaca

Auto-generated profile, based on publicly available information

Celina Borges Migliavaca

HTA Unit, Inova Medical, Porto Alegre, Brazil

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Research Synthesis Methods
Verified
Journal Article
Closed access
PDF file
CMCelina Borges Migliavaca
Celina Borges Migliavaca
CSCinara Stein
Cinara Stein
VCVerônica Colpani
Verônica Colpani
TBTim Barker
Tim Barker
PZPatricia Klarmann Ziegelmann
Patricia Klarmann Ziegelmann
P(Prevalence Estimates Reviews—Systematic Review Methodology Group (PERSyst)
Prevalence Estimates Reviews—Systematic Review Methodology Group (PERSyst)

26 April 2020 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
O(on behalf of the Prevalence Estimates Reviews – Systematic Review Methodology Group (PERSyst)
on behalf of the Prevalence Estimates Reviews – Systematic Review Methodology Group (PERSyst)
CMCelina Borges Migliavaca
Celina Borges Migliavaca
CSCinara Stein
Cinara Stein
VCVerônica Colpani
Verônica Colpani
TBTim Barker
Tim Barker
MFMaicon Falavigna
Maicon Falavigna
Background: There is a notable lack of methodological and reporting guidance for systematic reviews of prevalence data. This information void has the potential to result in reviews that are inconsistent and inadequate to inform healthcare policy and decision making. The aim of this meta-epidemiological study is to describe the methodology of recently published prevalence systematic reviews. Methods: We searched MEDLINE (via PubMed) from February 2017 to February 2018 for systematic reviews of prevalence studies. We included systematic reviews assessing the prevalence of any clinical condition using patients as the unit of measurement and we summarized data related to reporting and methodology of the reviews. Results: A total of 235 systematic reviews of prevalence were analyzed. The median number of authors was 5 (interquartile range [IQR] 4–7), the median number of databases searched was 4 (3–6) and the median number of studies included in each review was 24 (IQR 15–41.5). Search strategies were presented for 68% of reviews. Forty five percent of reviews received external funding, and 24% did not provide funding information. Twenty three percent of included reviews had published or registered the systematic review protocol. Reporting guidelines were used in 72% of reviews. The quality of included studies was assessed in 80% of reviews. Nine reviews assessed the overall quality of evidence (4 using GRADE). Meta-analysis was conducted in 65% of reviews; 1% used Bayesian methods. Random effect meta-analysis was used in 94% of reviews; among them, 75% did not report the variance estimator used. Among the reviews with meta-analysis, 70% did not report how data was transformed; 59% percent conducted subgroup analysis, 38% conducted meta-regression and 2% estimated prediction interval; I2 was estimated in 95% of analysis. Publication bias was examined in 48%. The most common software used was STATA (55%). Conclusions: Our results indicate that there are significant inconsistencies regarding how these reviews are conducted. Many of these differences arose in the assessment of methodological quality and the formal synthesis of comparable data. This variability indicates the need for clearer reporting standards and consensus on methodological guidance for systematic reviews of prevalence data.

1 November 2020 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
CMCelina Borges Migliavaca
Celina Borges Migliavaca
CSCinara Stein
Cinara Stein
VCVerônica Colpani
Verônica Colpani
ZMZachary Munn
Zachary Munn
MFMaicon Falavigna
Maicon Falavigna
To identify items and domains applicable for the quality assessment of prevalence studies. We searched databases and grey literature to identify tools or guides about the quality assessment of prevalence studies. After study selection, we abstracted questions applicable for prevalence studies and classified into at least one of the following domains: 'Population and setting', 'Condition measurement', 'Statistics' and 'Other'. PROSPERO registration: CRD42018088437 RESULTS: We included 30 tools: 8 (26.7%) specifically designed to appraise prevalence studies and 22 (73.3%) adaptable for this purpose. We identified 12 unique items in the domain "Population and setting", 16 in the domain "Condition measurement" and 14 in the domain "Statistics". Of those, 25 (59.5%) were identified in the eight specific tools. Regarding the domain "Other", we identified 77 unique items, mainly related to manuscript writing and reporting (n=48, 62.3%); of those, 24 (31.2%) were identified in the eight specific tools and 53 (68.8%) in the additional 22 non-specific tools. We provide a comprehensive set of items classified by domains that can guide the appraisal of prevalence studies, conduction of primary prevalence studies, and update or development of tools to evaluate prevalence studies.

20 August 2018 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
CSCinara Stein
Cinara Stein
CMCelina Borges Migliavaca
Celina Borges Migliavaca
VCVerônica Colpani
Verônica Colpani
PRPriscila Raupp da Rosa
Priscila Raupp da Rosa
DSDaniel Sganzerla
Daniel Sganzerla
MFMaicon Falavigna
Maicon Falavigna
Chagas disease is a neglected chronic condition caused by Trypanosoma cruzi, with high prevalence and burden in Latin America. Ventricular arrhythmias are common in patients with Chagas cardiomyopathy, and amiodarone has been widely used for this purpose. The aim of our study was to assess the effect of amiodarone in patients with Chagas cardiomyopathy. We searched MEDLINE, Embase and LILACS up to January 2018. Data from randomized and observational studies evaluating amiodarone use in Chagas cardiomyopathy were included. Two reviewers selected the studies, extracted data and assessed risk of bias. Overall quality of evidence was accessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE). We included 9 studies (3 before-after studies, 5 case series and 1 randomized controlled trial). Two studies with a total of 38 patients had the full dataset, allowing individual patient data (IPD) analysis. In 24-hour Holter, amiodarone reduced the number of ventricular tachycardia episodes in 99.9% (95%CI 99.8%-100%), ventricular premature beats in 93.1% (95%CI 82%-97.4%) and the incidence of ventricular couplets in 79% (RR 0.21, 95%CI 0.11–0.39). Studies not included in the IPD analysis showed a reduction of ventricular premature beats (5 studies), ventricular tachycardia (6 studies) and ventricular couplets (1 study). We pooled the incidence of adverse side effects with random effects meta-analysis; amiodarone was associated with corneal microdeposits (61.1%, 95%CI 19.0–91.3, 5 studies), gastrointestinal events (16.1%, 95%CI 6.61–34.2, 3 studies), sinus bradycardia (12.7%, 95%CI 3.71–35.5, 6 studies), dermatological events (10.6%, 95%CI 4.77–21.9, 3 studies) and drug discontinuation (7.68%, 95%CI 4.17–13.7, 5 studies). Quality of evidence ranged from moderate to very low. Amiodarone is effective in reducing ventricular arrhythmias, but there is no evidence for hard endpoints (sudden death, hospitalization). Although our findings support the use of amiodarone, it is important to balance the potential benefits and harms at the individual level for decision-making. Chagas disease is a chronic neglected tropical disease, with high prevalence and burden in Latin America. About 30% of chronically infected patients develop Chagas cardiomyopathy. Ventricular arrhythmias are common in patients with Chagas cardiomyopathy and treatment approaches include medications, resynchronization therapy, and implantable cardioverter defibrillator. Studies published from 1980 to 1990 have evaluated the effect of amiodarone. According to our systematic review and individual patient meta-analysis, amiodarone reduced ventricular tachycardia, ventricular premature beats and incidence of ventricular couplets. Although the strong evidence of clinical benefit with arrhythmia reduction, this information should be interpreted with caution, since arrhythmia is a surrogate outcome and since its clinical impact on death and hospitalization reduction over time is not clear. Little information was identified related to hard endpoints. Regarding side effects, our systematic review observed that amiodarone was associated with corneal microdeposits, gastrointestinal events, sinus bradycardia, dermatological events, pneumonitis, hypothyroidism and drug discontinuation. The currently available evidence shows that amiodarone seems to be an effective antiarrhythmic drug for patients with Chagas disease, especially in settings where an implantable cardioverter defibrillator is not available or affordable, but that a balance between potential benefits and harms at the individual level is needed.

26 July 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
RCRodolfo Delfini Cançado
Rodolfo Delfini Cançado
FCFernando - prédio II - lab. Inflamação Ferreira Costa
Fernando - prédio II - lab. Inflamação Ferreira Costa
CLClarisse Lobo
Clarisse Lobo
CMCelina Borges Migliavaca
Celina Borges Migliavaca
MFMaicon Falavigna
Maicon Falavigna
APAna Cristina Silva Pinto
Ana Cristina Silva Pinto
Sickle cell disease (SCD) is a group of hereditary chronic diseases with a substantial impact on quality of life and morbimortality. In Brazil, it is 1 of the most common hereditary diseases; however, there are sparse epidemiological data for the country. Using data from death certificates, we aimed to estimate the median age at death, years of life lost because of SCD, and the median survival. From 2015 to 2019, we identified 3320 records of deaths of individuals with SCD, from a total of 6 553 132 death records. Among individuals with SCD, the median age at death was 37 years less than that of the general population (SCD: aged 32.0 years at death, interquartile range [IQR], 19.0-46.0; general population: aged 69.0 years at death; IQR, 53.0-81.0). Results were consistent when stratified by sex or race. Over the 5 years evaluated, crude death rates varied from 0.30 to 0.34 per 100 000 inhabitants (mean 0.32 per 100 000 inhabitants). We estimated a prevalence of 60 017 individuals living with SCD (29.02 cases per 100 000) and an average incidence of 1362 cases yearly. The median estimated survival was 40 years for individuals with SCD and 80 years for the general population. SCD was associated with an increased risk of mortality in most age ranges. Among individuals with SCD aged between 1 and 9 years and between 10 and 39 years, the risk of death was 32 and 13 times higher, respectively. The most common causes of death were sepsis and respiratory failure. These results highlight the burden of SCD in Brazil and the necessity of improved care for this population.

6 April 2022 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
CSCinara Stein
Cinara Stein
LHLucas Helal
Lucas Helal
CMCelina Borges Migliavaca
Celina Borges Migliavaca
CSCaroline Nicola Sangalli
Caroline Nicola Sangalli
VCVerônica Colpani
Verônica Colpani
MFMaicon Falavigna
Maicon Falavigna